RT Journal Article
SR Electronic
T1 Erectile Dysfunction as a Novel Biomarker for The Onset of Cardiometabolic Vascular Disease Risk in the Aging Male: A Systematic Review and Meta-Analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.06.24310031
DO 10.1101/2024.07.06.24310031
A1 Borges, Julian Yin Vieira
YR 2024
UL http://medrxiv.org/content/early/2024/07/12/2024.07.06.24310031.abstract
AB Background and Objective Vascular Erectile dysfunction (ED) is considered a sentinel marker for underlying cardiovascular and metabolic disorders. This systematic review and meta-analysis aim to quantify the predictive value of ED for cardiometabolic vascular diseases (CVD) in young adults as well as aging males and to explore the temporal relationship between ED onset and the development of these diseases.Methods A comprehensive search of databases including PubMed, EMBASE, and Cochrane Library was conducted to identify relevant studies. Inclusion criteria were studies assessing the association between ED and CVD, with effect sizes reported as odds ratios (ORs) or hazard ratios (HRs). Data were extracted and pooled using random-effects meta-analysis. Sensitivity analyses, including leave-one-out analysis, and Egger’s test for publication bias, were performed.Key Findings and LimitationsThe pooled analysis of 39 studies revealed a significant association between ED and CVD with an OR of 1.42 (95% CI: 1.28-1.57).The temporal relationship indicates that ED precedes the onset of CVD by approximately 2 to 5 years.Endothelial dysfunction, a common pathway in ED and CVD, was highlighted through biomarkers such as flow-mediated dilation (FMD), nitric oxide (NO) levels, and C-reactive protein (CRP).Limitations include heterogeneity among study designs and the potential for residual confounding.Conclusions and Clinical Implications ED is a robust predictive biomarker for CVD in aging males, with significant implications for early detection and preventive strategies. Clinicians should consider cardiovascular risk assessment in patients presenting with ED to facilitate timely intervention and improve long-term outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors